Shire PLC plans to resubmit its application for US approval of a potential blockbuster drug for dry-eye disease next year after regulators unexpectedly asked for additional testing and information.
“We were disappointed” by the feedback on the medicine, called lifitegrast, CEO Flemming Ornskov said in a statement, adding that the Dublin-based drugmaker would soon get data from an advanced study called Opus-3 that might help with a resubmission to the US Food and Drug Administration (FDA).
Lifitegrast is one of the medicines in development that Shire is counting on to meet a goal of boosting sales to US$10 billion by 2020 from about US$6 billion last year.
Annual revenue from the drug could reach US$723 million by that date, according to the average of analyst estimates compiled by Bloomberg.
The company said late on Friday that the FDA had requested another clinical study and data on product quality, a setback after the drug had won priority review status, shortening the review process to eight months from the standard 12 months.
“Opus-3 has now been completed and top-line data are expected before the end of the year,” Ornskov said in the statement yesterday. “If the study is positive, we plan to refile our lifitegrast submission in the first quarter of 2016, and will remain on track for the planned launch next year.”
Opus-3 is “very likely” to show that it improves symptoms in patients, said David Evans, an analyst at UBS Group AG in London.
This would add evidence to two previous studies, neither of which hit both primary goals, he said.
In a research note earlier this month, Evans correctly predicted the FDA would want more data for the drug, which may at its peak hit US$2 billion in annual sales. He also said he expects it to eventually reach the market.
“We see a high probability of refiling and ultimate approval,” Evans said in the note.
Shire said that in the US there are 29 million adults who have the symptoms of dry-eye disease. The condition makes it more difficult to perform certain activities, including using a computer or reading for an extended period of time. Lifitegrast, if approved, would compete with Allergan PLC’s Restasis, which is estimated to bring in more than US$1 billion in sales this year.
‘SWASTICAR’: Tesla CEO Elon Musk’s close association with Donald Trump has prompted opponents to brand him a ‘Nazi’ and resulted in a dramatic drop in sales Demonstrators descended on Tesla Inc dealerships across the US, and in Europe and Canada on Saturday to protest company chief Elon Musk, who has amassed extraordinary power as a top adviser to US President Donald Trump. Waving signs with messages such as “Musk is stealing our money” and “Reclaim our country,” the protests largely took place peacefully following fiery episodes of vandalism on Tesla vehicles, dealerships and other facilities in recent weeks that US officials have denounced as terrorism. Hundreds rallied on Saturday outside the Tesla dealership in Manhattan. Some blasted Musk, the world’s richest man, while others demanded the shuttering of his
ADVERSARIES: The new list includes 11 entities in China and one in Taiwan, which is a local branch of Chinese cloud computing firm Inspur Group The US added dozens of entities to a trade blacklist on Tuesday, the US Department of Commerce said, in part to disrupt Beijing’s artificial intelligence (AI) and advanced computing capabilities. The action affects 80 entities from countries including China, the United Arab Emirates and Iran, with the commerce department citing their “activities contrary to US national security and foreign policy.” Those added to the “entity list” are restricted from obtaining US items and technologies without government authorization. “We will not allow adversaries to exploit American technology to bolster their own militaries and threaten American lives,” US Secretary of Commerce Howard Lutnick said. The entities
Minister of Finance Chuang Tsui-yun (莊翠雲) yesterday told lawmakers that she “would not speculate,” but a “response plan” has been prepared in case Taiwan is targeted by US President Donald Trump’s reciprocal tariffs, which are to be announced on Wednesday next week. The Trump administration, including US Secretary of the Treasury Scott Bessent, has said that much of the proposed reciprocal tariffs would focus on the 15 countries that have the highest trade surpluses with the US. Bessent has referred to those countries as the “dirty 15,” but has not named them. Last year, Taiwan’s US$73.9 billion trade surplus with the US
Prices of gasoline and diesel products at domestic gas stations are to fall NT$0.2 and NT$0.1 per liter respectively this week, even though international crude oil prices rose last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. International crude oil prices continued rising last week, as the US Energy Information Administration reported a larger-than-expected drop in US commercial crude oil inventories, CPC said in a statement. Based on the company’s floating oil price formula, the cost of crude oil rose 2.38 percent last week from a week earlier, it said. News that US President Donald Trump plans a “secondary
RSS